stockrow
Monday 9 November 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIUAC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
- Revenue
- +152.3%
- EPS
- +36.0%
- Free cash flow
- +4.66%
Quarter to September 2026, against a year earlier
2.23
0.12
+5.69%
Follow ACIU
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(93.59%) | (113.59%) | 0.00% | (122.01%) | |
| (37.92%) | (70.48%) | 0.00% | (33.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,753.26%) | 639.62% | 0.00% | 414.09% | |
Average Days of Receivables |
99.90 | 128.71 | 0.00 | 248.92 | |
Free Cash Flow per Share |
(0.84) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(84.67) | — | (83.67) | — | |
Capital Expenditures |
(1.07) | — | (1.21) | — | |
| Other line items | |||||
Cash ROIC |
(51.47%) | 0.00% | (59.83%) | 0.00% | |
Accounts Receivable Turnover |
3.54 | 2.41 | 0.00 | 2.08 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
1,579.52% | 1,409.69% | — | 810.37% | |
Selling, General and Administrative Expense of Revenue |
450.44% | 426.99% | — | 275.49% | |
Share Based Compensation of Revenue |
123.03% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(362.82) | (319.62) | — | (262.08) | |
Operating CF/Net income |
0.98 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
1.26 | 0.00 | 1.49 | 0.00 | |
Capex/Depreciation |
(0.35) | — | (0.33) | — | |
Revenue per Share |
0.04 | 0.05 | — | 0.10 | |
Operating CF per Share |
(0.83) | 0.00 | 0.00 | 0.00 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.25 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026